MIRA Pharmaceuticals Inc. (MIRA)
NASDAQ: MIRA
· Real-Time Price · USD
1.15
-0.01 (-0.86%)
At close: May 01, 2025, 3:49 PM
-0.86% (1D)
| Bid | 1.09 |
| Market Cap | 19.25M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -7.85M |
| EPS (ttm) | -0.51 |
| PE Ratio (ttm) | -2.25 |
| Forward PE | -2.18 |
| Analyst | Buy |
| Ask | 1.2 |
| Volume | 230,378 |
| Avg. Volume (20D) | 1,170,713 |
| Open | 1.18 |
| Previous Close | 1.16 |
| Day's Range | 1.14 - 1.18 |
| 52-Week Range | 0.51 - 5.01 |
| Beta | 2.07 |
About MIRA
MIRA Pharmaceuticals, Inc. operates as a clinical development stage biopharmaceutical company. The company focuses on the development and commercialization of a new molecular synthetic tetrahydrocannabinol (THC) analog under investigation for the treatment of adult patients with anxiety and cognitive decline typically associated with early-stage dementia. It is developing MIRA1a, a synthetic cannabinoid analog to treat anxiety and chronic pain by...
Industry Drug Manufacturers - General
Sector Healthcare
IPO Date Aug 14, 2023
Employees 2
Stock Exchange NASDAQ
Ticker Symbol MIRA
Website https://mirapharmaceuticals.com
Analyst Forecast
According to 2 analyst ratings, the average rating for MIRA stock is "Buy." The 12-month stock price forecast is $14, which is an increase of 1122.71% from the latest price.
Stock Forecasts2 weeks ago
+19.26%
MIRA Pharmaceuticals shares are trading higher aft...
Unlock content with
Pro Subscription
6 months ago
+21.71%
MIRA Pharmaceutical shares are trading higher after the company's new preclinical data showed that Ketamir-2 achieved 60% greater efficacy than the FDA-approved gabapentin in reducing chemotherapy-induced pain.
